TP53 and lung carcinoma: Sub-analysis revealed that TP53-CHIP was associated with lung cancer mortality [Fig. 2C; HR, 1.74; 95% CI, 1.31–2.30; P (Wald test) = 1.12 × 10−4], chronic lower respiratory tract disease mortality [Fig. 2D; HR, 2.64; 95% CI, 1.52–4.59; P (Wald test) = 5.93 × 10−4], and interstitial pneumonia mortality [Fig. 2D; HR, 3.12; 95% CI, 1.76–5.56; P (Wald test) = 1.07 × 10−4].